Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Human CXCR1/IL-8RA Antibody, R&D Systems™

Mouse Monoclonal Antibody
Supplier: R&D Systems MAB330R100
This item is not returnable.
View return policy
Description
CXCR1/IL-8RA Monoclonal specifically detects CXCR1/IL-8RA in Human samples. It is validated for Flow Cytometry, Immunohistochemistry, Neutralization, CyTOF-reported.Specifications
CXCR1/IL-8RA | |
Monoclonal | |
Unconjugated | |
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. | |
CD128, CD181, CD181 antigen, CDw128aC-C, chemokine (C-X-C motif) receptor 1, CKR-1, CMKAR1, C-X-C chemokine receptor type 1, CXC-R1, CXCR-1, High affinity interleukin-8 receptor A, IL-8 RA, IL-8 receptor type 1, IL-8R A, IL8R1, IL8RA, IL8RAC-C-CKR-1, IL8RBA, interleukin 8 receptor, alpha, interleukin-8 receptor type 1, interleukin-8 receptor type A | |
NS0 mouse myeloma cell line transfected with human CXCR1/IL-8 RA, Met1-Leu350, Accession No. AAA59159 | |
100 μg | |
3577.0 | |
Reconstitute at 0.5 mg/mL in sterile PBS. | |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month, 2 to 8°C under sterile conditions after reconstitution. 6 months, -20 to -70°C under sterile conditions after reconstitution. | |
IgG2a |
Flow Cytometry, Immunohistochemistry, Neutralization, CyTOF | |
42705R | |
Flow Cytometry 0.25 ug/10^6 cells, Immunohistochemistry 0.5-25 ug/mL, Neutralization 0.4-2 ug/mL, CyTOF-reported | |
AAA59159 | |
Mouse | |
Protein A or G purified from cell culture supernatant | |
Primary | |
Detects human CXCR1/IL-8 RA transfectants but not the parental cell line. | |
Human | |
Supernatant |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction